This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Institutional Ownership Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Elicio Therapeutics (NASDAQ:ELTX)CurrentInstitutional OwnershipPercentage35.03%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$727.40KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$152.75K Get ELTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Elicio Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ELTX Institutional Buying and Selling by Quarter Elicio Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails4/28/2025 Moody Lynn & Lieberson LLC10,000$62K0.0%N/A0.093% 2/7/2025CM Management LLC40,000$204K0.2%-20.0%0.371% 8/15/2024Armistice Capital LLC100,000$411K0.0%N/A0.978% 8/9/2024Warberg Asset Management LLC11,801$49K0.0%N/A0.115% 8/2/2024CM Management LLC50,000$206K0.2%-33.3%0.489% 5/14/2024CM Management LLC75,000$570K0.5%+50.0%0.733% 8/4/2023CM Management LLC65,000$618K0.6%N/A2.159% (Data available from 1/1/2016 forward) ELTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ELTX shares? During the previous two years, the following institutional investors and hedge funds held shares of Elicio Therapeutics shares: Armistice Capital LLC ($411K), CM Management LLC ($204K), and Moody Lynn & Lieberson LLC ($62K), Warberg Asset Management LLC ($49K).Learn more on ELTX's institutional investors. What percentage of Elicio Therapeutics stock is owned by institutional investors? 35.03% of Elicio Therapeutics stock is owned by institutional investors. Learn more on ELTX's institutional investor holdings. Which institutional investors have been buying Elicio Therapeutics stock? The following institutional investors have purchased Elicio Therapeutics stock in the last 24 months: Armistice Capital LLC ($100K), CM Management LLC ($90K), Warberg Asset Management LLC ($11.80K), and Moody Lynn & Lieberson LLC ($10K). How much institutional buying is happening at Elicio Therapeutics? Institutional investors have bought a total of 211,801 shares in the last 24 months. This purchase volume represents approximately $1.34M in transactions. Which Elicio Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Elicio Therapeutics stock in the last 24 months: CM Management LLC ($35K). How much institutional selling is happening at Elicio Therapeutics? Institutional investors have sold a total of 35,000 shares in the last 24 months. This volume of shares sold represents approximately $152.75K in transactions. Related Companies NGNE Institutional Ownership ELDN Institutional Ownership IVA Institutional Ownership FULC Institutional Ownership ANNX Institutional Ownership YMAB Institutional Ownership RZLT Institutional Ownership GOSS Institutional Ownership ESPR Institutional Ownership HURA Institutional Ownership This page (NASDAQ:ELTX) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
